Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report.

摘要: BACKGROUND: Although US year 2000 guidelines recommended characterizing breast cancers by human epidermal growth factor receptor 2 (HER2), national cancer registries do not collect HER2, rendering a population-based understanding of HER2 and clinical “triple subtypes” (estrogen [ER] / progesterone [PR] HER2) largely unknown. We document the prevalence testing status, triple subtypes present first report subtype incidence rates. METHODS: Medical records were searched for on 1842 metropolitan Atlanta females diagnosed with during 2003-2004. testing/status analyzed age, race/ethnicity, tumor factors, socioeconomic treatment. Age-adjusted rates calculated. RESULTS: Over 90% cases received testing: 12.6% positive, 71.7% negative, 15.7% compliance was significantly better women who younger, Caucasian or African-American descent, early stage disease. Incidence (per 100,000) 21.1 HER2+ tumors 27.8 triple-negative tumors, latter differing race (36.3 19.4 black white women, respectively). CONCLUSIONS: HER2 recommendations are uniformly adhered to. differ age/race. As biologic knowledge is translated into setting eg, as biomarker, it will be incumbent upon to this information. cautiously extrapolate an annual burden 3000 17,000 respectively, among 5000 16,000 respectively. Testing, rate, variations warrant in-depth exploration translation. Cancer 2010. © 2010 American Society.